Affiliations: Fox Chase Cancer Center, Department of Surgical Oncology, 333 Cottman Avenue, Philadelphia, PA 19111, USA | NCI, NIH, Bethesda, MD, USA
Correspondence:
[*]
Corresponding author: Monica Morrow, MD, Chairman, Department of Surgical Oncology, G. Willing Pepper Chair in Cancer Research, Department of Surgery, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. Tel.: +1 215 728 3096; Fax: +1 215 214 4035; E-mail: Monica.Morrow@fccc.edu
Abstract: Mastectomy alone as a treatment for inflammatory breast cancer results in local recurrence in 20% of cases and a median survival of only 2 years. Current management of inflammatory cancer employs initial chemotherapy with surgery reserved for patients who have complete resolution of inflammatory changes. The combination of chemotherapy, mastectomy, and radiotherapy results in local control in 80% of patients. Breast conserving surgery and sentinel node biopsy are contraindicated in inflammatory cancer.
DOI: 10.3233/BD-2006-22108
Journal: Breast Disease, vol. 22, no. 1, pp. 67-73, 2006
